The 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held in Madrid from October 29 to November 1, 2024, set the stage for groundbreaking updates in Alzheimer’s research, as pharmaceutical leaders presented their latest findings on novel therapies and cutting-edge clinical trials. With an ever-growing urgency to tackle this devastating disease, the event attracted top industry players who shared pivotal insights into the future of Alzheimer’s, a disease with a prevalence of approximately 6.9 million in the US alone with 97% of the patients aged 65 and above, as per Delveinsight’s estimates in Alzheimer's Disease Epidem Report. The conference illuminated ...
